The Role of Antidepressants in the Management of Fibromyalgia Syndrome: A Systematic Review and Meta-Analysis
CNS Drugs,  Evidence Based Medicine  Clinical Article

Hauser W et al. – The tricyclic antidepressant (TCA) amitriptyline and the serotonin noradrenaline (norepinephrine) reuptake inhibitors (SNRIs) duloxetine and milnacipran are first–line options for the treatment of fibromyalgia syndrome (FMS) patients. Physicians and patients should be realistic about the potential benefits of antidepressants in FMS. A small number of patients experience a substantial symptom relief with no or minor adverse effects. However, a remarkable number of patients dropout of therapy because of intolerable adverse effects or experience only a small relief of symptoms, which does not outweigh the adverse effects.

Methods
  • Studies with a randomized controlled trial (RCT) design comparing any types of antidepressants with pharmacological placebo or head–to–head comparisons of different types of antidepressants in FMS patients were included.
  • RCTs in which antidepressants were combined with any other defined treatment or antidepressants were tested against anything but drug placebo were excluded.
  • Patients diagnosed with FMS according to predefined criteria of any age were included.
  • To be included, studies had to assess at least one key domain of FMS (pain, sleep, fatigue, health–related quality of life [HRQOL]) as outcomes of efficacy and report total treatment discontinuation rates and/or dropout rates due to adverse events as outcomes for harms.
  • Data were extracted according to protocols of previous systematic reviews on antidepressants in FMS.
  • Methodology quality was assessed by the van Tulder score.
  • Standardized mean differences (SMD) were calculated for continuous outcomes by means and standard deviations and relative risks (RR) for 30% pain reduction and total dropout rate for comparisons of antidepressants with placebo.
  • Examination of the combined results was performed by a random effects model.
  • The authors used Cohen's categories to evaluate the magnitude of the effect size, calculated by SMD.
  • Heterogeneity was tested by the I2 statistic.
  • Thirty–five studies were included in the meta–analysis.

Results
  • The SMDs of serotonin noradrenaline (norepinephrine) reuptake inhibitors (SNRIs) on pain, sleep, fatigue, depression and HRQOL were significant.
  • Based on Cohen's categories, the effect size on pain was small and the ones on sleep, fatigue, depression and HRQOL were not substantial.
  • 1481/3528 (42.0%) patients with SNRIs and 737/2304 (32.0%) patients with placebo reported a 30% pain reduction (number needed to treat [NNT] 10.0; 95% CI 8.00, 13.4; I2=4%).
  • The RR of dropouts due to adverse events was 1.83 (95% CI 1.53, 2.18; I2=33%).
  • The SMDs of selective serotonin reuptake inhibitors (SSRIs) on pain, sleep, depression and HRQOL were significant.
  • Based on Cohen's categories, the effect sizes on pain, depression and HRQOL were small and the one on sleep not substantial.
  • 72/198 (36.4%) patients with SSRIs and 40/194 (20.6%) patients with placebo reported a 30% pain reduction (NNT 6.3; 95% CI 4.1, 14.1).
  • The RR of dropouts due to adverse events was 1.60 (95% CI 0.84, 3.04; I2=0%).
  • The SMDs of tricyclic antidepressants (TCAs) on pain, sleep, fatigue and HRQOL were significant.
  • Based on Cohen's categories, the effect sizes on pain and sleep were moderate and the ones on fatigue and HRQOL were small.
  • 140/290 (48.3%) patients with TCAs and 70/252 (27.8%) patients with placebo reported a 30% pain reduction (NNT 4.9; 95% CI 3.5, 8.0).
  • The RR of dropouts due to adverse events was 0.84 (95% CI 0.46, 1.52; I2=0%).

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Psychiatry

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Psychiatry Articles

1 Zolpidem and the risk of Parkinson's disease: A nationwide population-based study Journal of Psychiatric Research, August 1, 2014    Clinical Article

2 Vascular Endothelial Growth Factor: A potential diagnostic biomarker for major depression Journal of Psychiatric Research, September 19, 2014    Clinical Article

3 Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials JAMA Psychiatry, October 22, 2014    Evidence Based Medicine    Clinical Article

4 Comparative efficacy and acceptability of drug treatments for bipolar depression: A multiple-treatments meta-analysis Acta Psychiatrica Scandinavica, October 10, 2014    Evidence Based Medicine    Clinical Article

5 Antidepressants and the risk of hyponatraemia: A class-by-class review of the literature Psychosomatics, September 15, 2014    Review Article

6 Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis Schizophrenia Research, September 24, 2014    Clinical Article

7 Comparison of pro-inflammatory cytokines among patients with bipolar disorder and unipolar depression and normal controls Bipolar Disorders, October 3, 2014    Clinical Article

8 Diffusion tensor imaging predictors of treatment outcomes in major depressive disorder The British Journal of Psychiatry, October 8, 2014    Clinical Article

9 A comparison between phone-based psychotherapy with and without text messaging support in between sessions for crisis patients Full Text Journal of Medical Internet Research, October 13, 2014    Free full text    Clinical Article

10 Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression International Journal of Neuropsychopharmacology, October 2, 2014    Clinical Article

11 Association of ARRB1 polymorphisms with the risk of major depressive disorder and with treatment response to mirtazapine Journal of Psychopharmacology, October 16, 2014    Clinical Article

12 Cognitive improvement of attention and inhibition in the late afternoon in children with attention-deficit hyperactivity disorder (ADHD) treated with osmotic-release oral system methylphenidate Journal of Child Neurology, October 15, 2014    Clinical Article

13 Prazosin in the treatment of PTSD Journal of Psychiatric Practice, July 25, 2014    Review Article

14 Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis European Neuropsychopharmacology, September 2, 2014    Evidence Based Medicine    Review Article

15 Attention-deficit/hyperactivity disorder and adverse health outcomes in adults The Journal of Nervous and Mental Disease, October 29, 2014    Clinical Article

16 Therapist-assisted Internet–delivered Cognitive Behavior Therapy for depression and anxiety: Translating evidence into clinical practice Journal of Anxiety Disorders, October 17, 2014    Clinical Article

17 Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia American Journal of Psychiatry, October 6, 2014    Evidence Based Medicine    Clinical Article

18 Internet-delivered exposure-based cognitive-behavioural therapy and behavioural stress management for severe health anxiety: Randomised controlled trial The British Journal of Psychiatry, October 14, 2014    Clinical Article

19 Psychiatric correlates of alcohol and tobacco use disorders in U.S. adults aged 65 years and older: Results from the 2001-2002 National Epidemiologic Survey of Alcohol and Related Conditions The American Journal of Geriatric Psychiatry, October 9, 2014    Clinical Article

20 Cigarette smoking and the onset and persistence of depression among adults in the United States: 1994-2005 Comprehensive Psychiatry, October 28, 2014    Clinical Article

Indexed Journals in Psychiatry : Current Psychiatry, Bipolar Disorders, American Journal of Psychiatry, Addictionmore